You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
A股異動丨恆瑞醫藥(600276.SH)大漲超7% 今年累漲近80%
格隆匯 08-23 11:19
恆瑞醫藥(600276.SH)早盤股價持續走高,現漲7.77%,報77.3元,暫成交17.69億元,最新總市值為3418.83億元。恆瑞醫藥股價今年以來漲幅近80%。 8月18日,恆瑞醫藥總經理周雲曙宣佈艾瑞卡(藥品名稱:注射用卡瑞利珠單抗)正式上市,此舉標誌着國產PD-1原研藥的進一步成熟化與市場化,中國腫瘤免疫原研藥正式登上歷史舞台。醫藥行業研究員表示,對恆瑞而言,艾瑞卡上市意味着其在抗癌藥領域獲得了一個重磅品種,同時增強其抗癌藥產品間的協同效應。目前國內企業獲批的抗PD-1單抗藥品屬於小適應症,對應市場相對較小,未來的競爭態勢取決於2-3年內各家企業在其他適應症的開發策略和進度。(行情來源:富途證券)
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account